<DOC>
	<DOCNO>NCT02070796</DOCNO>
	<brief_summary>The primary objective study establish Bioequivalence ( BE ) 2 different formulation 2 mg/24 hr ( 10 cm^2 ) Rotigotine transdermal patch Chinese subject .</brief_summary>
	<brief_title>Single-site , Open-label , Randomized , Cross-over Study Healthy Chinese Subjects Evaluate Bioequivalence Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations</brief_title>
	<detailed_description>Bioequivalence conclude 90 % Confidence Intervals ( CIs ) ratio Treatment A/Treatment B fully include acceptance range 0.8-1.25 AUC ( 0-t ) AUC , within acceptance range 0.7 1.43 Cmax .</detailed_description>
	<mesh_term>N 0437</mesh_term>
	<criteria>An Independent Ethics Committee ( IEC ) approve write Informed Consent form sign date subject Subject consider reliable capable adhere protocol , visit schedule , patch application accord judgment investigator Subject willing able comply study requirement Subject Chinese ( 4 grandparent Chinese origin , well ) , male , age 18 40 year ( inclusive ) Subject healthy ( clinically significant finding investigation Eligibility Assessment ( EA ) ) Subject body mass index 19 kg/m² 24 kg/m² ( inclusive ) , body weight great equal 50 kg Subject agree practice medically accept method contraception ( eg , condom , spermicide ) unless sexually abstinent duration study 3 month final patch application Subject previously participate study subject previously assign treatment Rotigotine study Subject participate another study Investigational Medicinal Product ( IMP ) ( medical device ) within previous 3 month currently participate another study IMP ( medical device ) Subject history diagnosis , counseling , treatment chronic alcohol drug abuse within previous 2 year Subject know clinically significant allergy know suspect clinically significant drug hypersensitivity component IMP comparable drug , opinion investigator , could jeopardize would compromise subject 's ability participate study Subject lifetime history suicide attempt Subject history significant skin hypersensitivity adhesives transdermal product recently unresolved contact dermatitis Subject medical psychiatric condition , opinion investigator , could jeopardize would compromise subject 's ability participate study Subject history present condition epilepsy and/or seizure Subject history present condition atopic eczematous dermatitis , psoriasis , and/or active skin disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Transdermal Patch</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>